第十届世界肺癌会议英文
2023_sabcs_year_in_review_概述及范文模板
2023 sabcs year in review 概述及范文模板1. 引言1.1 概述2023年SABCS（San Antonio Breast Cancer Symposium）是一次重要的国际学术会议，聚焦于乳腺癌研究领域。
该会议汇集了来自世界各地的乳腺癌专家、科学家和医生，共同分享他们在这一领域取得的最新研究成果和临床实践经验。
2023年SABCS以其广泛的议题涵盖范围以及高水平的研究发现而备受关注。
1.2 文章结构本文将按照以下结构进行概述和回顾2023年SABCS学术会议：- 引言：对本文进行开场介绍，指明论文目录结构。
- 第一章：总结第一章节讨论的要点，并提供相关细节和重要发现。
- 第二章：总结第二章节讨论的要点，并提供相关细节和重要发现。
- 第三章：总结第三章节讨论的要点，并提供相关细节和重要发现。
- 结论：全面总结2023年SABCS学术会议取得的成就，展望未来乳腺癌研究方向。
1.3 目的本文的目的是对2023年SABCS学术会议进行全面回顾和总结，向读者介绍该会议所涵盖的重要议题、相关研究成果以及临床应用前景。
通过梳理会议内容，我们旨在提供给读者一个清晰而全面的了解，促进乳腺癌领域研究与实践的发展。
同时，我们还将对未来乳腺癌研究方向和趋势进行一定程度上的探讨和展望。
最终，希望本文能够为读者提供洞察当代乳腺癌领域最新进展的视角，并为推动乳腺癌研究和防治工作做出贡献。
2. 第一章2.1 要点1：在2023年SABCS（San Antonio Breast Cancer Symposium）会议中，关于乳腺癌的研究和进展取得了许多重要成果。
其中一个重要的要点是关于乳腺癌的分子分类和个体化治疗策略的进展。
许多研究团队都探索了使用基因组学、转录组学和蛋白质组学等技术手段来对乳腺癌进行精确分类，并根据不同亚型的特征来制定相应的治疗方案。
2.2 要点2：另一个值得注意的要点是免疫治疗在乳腺癌领域的突破。
荟萃分析
荟萃分析百科名片荟萃分析，又称“Meta 分析”，Meta意指较晚出现的更为综合的事物，而且通常用于命名一个新的相关的并对原始学科进行评论的学问，不但包括数据结合，而且包括结果的流行病学探索和评价，以原始研究的发现取代个体作为分析实体。
荟萃分析产生的主要的理由是：对于多个单独进行的研究而言，许多观察组样本过小，难以产生任何明确意见。
目录荟萃分析-概述荟萃分析-荟萃分析的分类荟萃分析-IPD 荟萃分析的步骤荟萃分析-荟萃分析的优劣荟萃分析-荟萃分析的未来荟萃分析-概述荟萃分析-荟萃分析的分类荟萃分析-IPD 荟萃分析的步骤荟萃分析-荟萃分析的优劣荟萃分析-荟萃分析的未来展开编辑本段荟萃分析-概述荟萃分析的概念最早是由Light 和Smith 于1971 年提出的。
当时针对大量发表的科学论文中，对于同样的研究却得出截然不同的结果的问题，他们提出应该在全世界范围内收集对某一疾病各种疗法的小样本、单个临床试验的结果，对其进行系统评价和统计分析，将尽可能真实的科学结论及时提供给社会和临床医师，以促进推广真正有效的治疗手段，摈弃尚无依据的无效的甚至是有害的方法。
1976 年Glass 首次将这一概念命名为Meta-analysis（荟萃分析），并定义为一种对不同研究结果进行收集、合并及统计分析的方法。
这种方法逐渐发展成为一门新兴学科--“循证医学”的主要内容和研究手段。
荟萃分析的主要目的是将以往的研究结果更为客观的综合反映出来。
研究者并不进行原始的研究，而是将研究已获得的结果进行综合分析。
编辑本段荟萃分析-荟萃分析的分类通常概念下的文献综述是对有关文献的内容或结果进行罗列、简单的描述和初步的讨论，而荟萃分析则完全上了一个台阶。
根据荟萃分析所依据的基础或数据来源可以将其分为三类：文献结果荟萃分析（Meta-analysis based on literature, MAL）；综合或合并数据荟萃分析（Meta-analysis based on summary data, MAS）；独立研究原始数据荟萃分析（Meta-analysis based on individual patient data, MAP or IPD Meta-analysis）。
2011世界肺癌大会(WCLC)4篇恩度论文POST
2011世界肺癌大会（WCLC）4篇恩度论文POST1、Recombinant human endostatin normalizes tumor vasculature and alleviates hypoxia in Lewis lung carcinomasM. Chen, F. Peng, Z.M. Xu, J. Wang, Y. Bao, Y.Y. Chen, X. Hu, Y. Wang, Q.C. Zhou, H.L. MaSun Yat-Sen University Cancer Center/CHINA重组人血管内皮抑素（恩度）对Lewis肺癌的肿瘤血管正常化及改善乏氧作用，中山肿瘤医院陈明教授Background:Tumor vessels are structurally and functionally abnormal with defective endothelium, pericyte coverage, and basement membrane. Most antiangiogenic cancer therapies focus on the destruction of solid tumors by eradication of their supporting vasculature. However, antiangiogenic therapy may “normalize” the tumor vasculature for a short period of time, thereby providing a window of opportunity for enhanced sensitivity to radiation treatment.We investigated whether recombinant human endostatin created a “vascular normalization window” within tumors prior to vascular pruning to alleviate hypoxia in Lewis lung carcinomas in mice.Methods:(1)Kinetic changes in morphology of tumor vasculature in response to treatment with recombinant human endostatin were detected under a confocal microscope with immunofluorescent staining in Lewis lung carcinomas in mice.(2)The time course of hypoxic tumor fraction was assessed with immunohistochemical staining.(3)Effects on tumor growth were monitored as indicated in the growth curve of tumors.Results:Vascularity of the tumors was reduced over time by recombinant human endostatin treatment and significantly regressed for 9 days relative to the control group (Fig 1a-b). During recombinant human endostatin treatment, pericyte coverage increased by day3, increased markedly by day 5, and fell again by day 7 (Fig 1c-f). The vascular basement membrane (BM) was thin and closely associated with endothelial cells after recombinant human endostatin treatment, but appeared thickened, loosely associated with endothelial cells in control tumors (Fig 1g-n). The decrease in hypoxic tumor fraction on the 5th day after treatment was also found (Fig 2a). Tumor growth was not accelerated 5 days after recombinant human endostatin treatment (Fig 2b).Conclusion:Recombinant human endostatin can normalize tumor vasculature within day 3 to 7, leading to improved tumor oxygenation. The results provide important experimental basis for combining recombinant human endostatin with radiation therapy in human tumors.2、Circulating endothelial progenitor cells in resectable non-small cell lung cancer during adjuvant chemotherapy combined with endostarY. Yu, Z. Song, S. LuShanghai Chest Hospital, Jiaotong University, Shanghai/CHINA对于NSCLC术后辅助化疗联合恩度治疗中内皮祖细胞的研究，上海胸科医院陆舜教授Background:Antiangiogenic molecules can inhibit neovascularization in lung cancer, but their effect on circulating endothelial progenitor cells(cEPCs) is still unclear. Several hypotheses have been proposed that antiangiogenic drugs enhance the treatment efficacy of cytotoxic chemotherapy, including impairing the ability of tumors to regrow after therapy. Therefore, our study aims to examine the level of cEPCs (VEGFR2+ /CD133+) in the peripheral blood of resectable non-small cell lung cancer patients(NSCLC) treated by either chemotherapy combined with endostar(recombinant human endostatin) or chemotherapy alone as adjuvant therapy.Methods:Thirty three patients with resectable NSCLC were enrolled. Ten healthy individuals were as control. The blood samples of the patients were from a clinical trial(NCT01124253). Among them,18 patients treated by chemotherapy alone and 15 patients treated by chemotherapy combined with endostar. Peripheral blood was taken from the patients before surgery and after postoperative adjuvant therapy. Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll density gradient centrifugation. cEPCs labeled with VEGFR2, CD133 were counted by flow cytometry. Furthermore, we measured VEGFR2, CD133, CD34, and VE-cadherin mRNA in blood samples by means of a quantitative reverse transcription-PCR approach.Results:The percentage of cEPCs in the total PBMCs was 0.26%±0.14% in NSCLC patients without treatment intervention versus 0.045±0.032% in healthy controls( p = 0.00). There was a significant difference of cEPCs numbers in stage I—II compared with III ( p = 0.027) in the preoperative blood samples. The cEPCs numbers were significant lower in the combination therapy group than in chemotherapy alone group in the postoperative blood samples (p=0.014). Time to disease progression(TTP) in the patients with low cEPCs number (less than 0.35%) was longer than in those with high cEPCs number after adjuvant treatment (p =0.00, log rank). The preoperative VEGFR2 mRNA level was significantly correlated to disease progression ( p = 0.00, log rank test).Conclusion:This study showed that NSCLC patients had high cEPCs numbers. An early antiangiogenic therapy in combination with chemotherapy may be beneficial for the success of resectable NSCLC adjuvant therapy, and cEPCs may be a novel biomarker in those patients with no measurable targets.3、An Update of the Phase III Study of Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar (NPE) in Patients with Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC)J. He1, X. Zhang1, J. Li1, B. Han2, Y. Liu3, S. Wu4, Y. Kuang5, Y. Shen6, C. Chen7, Q. Wang8, Q. Li9, H. Ma10, S. Xu11, S. Xu12, P. Wang13, W. Mao14, Z. Pang5, S. Hou15, Y. Yang161Cancer Institute and Hospital, Chinese Academy of Medical Sciences/CHINA, 2Shanghai Jiaotong University Affiliated Shanghai Chest Hospital/CHINA, 3Liaoning Cancer Hospital & Institute/CHINA, 4The First Affiliated Hospital Of Wenzhou Medical College/CHINA, 5Jiangxi Cancer Hospital/CHINA, 6The Affiliated Hospital of Qingdao University Medical College/CHINA, 7Fujian Medical University Union Hospital/CHINA, 8Zhongshan Hospital Affiliated to Fudan University/CHINA, 9Sichuan Cancer Hospital/CHINA, 10The First Affiliated Hospital of Soochow University/CHINA, 11Harbin Medical University Cancer Hospital/CHINA, 12Beijing Chest Hospital/CHINA, 13The First People's Hospital of Yunnan Province/CHINA, 14Zhejiang Cancer Hospital/CHINA, 15Beijing Chaoyang Hospital/CHINA, 16Beijing Cancer Hospital/CHINAIB-IIIA NSCLC术后辅助NP联合恩度对比单纯NP方案的临床研究最新进展Background:Adjuvant chemotherapy demonstrated a 5-15% benefit in 5-year survival in early-stage NSCLC. However, it is clear that current therapies are far from satisfying. Endostar, a recombinant human Endostatin, could inhibit tumor angiogenesis. In a phase III trial, the addition of Endostar to NP regimen resulted in higher response rate, clinical benefit rate and longer median time to progression compared with NP alone in advanced NSCLC patients. In this study, we tried to investigate adjuvant NP regimen with or without Endostar in early-stage NSCLC patients.Methods:Completely resected patients (stage IB-IIIA) were randomized to receive adjuvant NP plus Endostar (arm A, Vinorelbine 25mg/m2 on d1 and d8 plus Cisplatin 80 mg/m2 intravenously, plus Endostar 7.5mg/m2 per day, iv, for 14 consecutive days. Every 21 days as one cycle, for 4 cycles) or NP regimen alone (arm B). The randomization was stratified by gender, stage and histology. The primary endpoint was overall survival (OS) and the secondary endpoints were relapse-free survival (RFS) and safety. Results:905 patients (arm A: 449; arm B: 456) from 43 centers in China were enrolled between 9/2007 and 12/2010. Two arms were well-balanced with regard to age, gender, histology, stage, and resection type.80 patients in arm A and 91 patients in arm B had relapsed disease. The median RFS was 27.7 months in arm A and 24.6 months in arm B (p=0.6009). 80.3% of patients in arm A finished 4 cycles of treatment and 77.8% of patients in arm B received 4 cycles of chemotherapy. Median survival time was not available at this moment because only very few patients had died. Grade 3/4 toxicities in arm A included leukopenia (58.4%), neutropenia (77.4%), anemia (13.1%), nausea (12.4%). Grade 3/4 toxicities in arm B included leukopenia (35.5%) neutropenia (61.6%), anemia (8.5%) and nausea (8.5%). It is worth noting that the incidence of cardiac toxicities in arm A (28.0%) was higher than that in arm B (21.1%).Conclusion:The preliminary result showed that patients in arm A experienced a longer median relapse-free survival time than in arm B (27.7 months vs. 24.6 months), although the difference was not statistically significant until now. The toxicity profiles for both arms were tolerable in this study. The patient follow-up is ongoing.4、A prospective phase I/II study of recombinant endostatin (endostar) combined with concurrent chemoradiotherapy in patients with unresectable stage III non-small cell lung cancer: a preliminary report M. Chen1, Y. Bao1, Q.C. Zhou1, X. Hu1, Z.H. Yu2, Y.C. Cai3, J.C. Li4, Z.B. Cheng5, L. Chen6, Y. Wang1, J. Wang1, F. Peng1, Z.M. Xu1, H.L. Ma1, R.B. Lu1, H.Q. Dai11Sun Yat-Sen University Cancer Center/CHINA, 2Affiliated Hospital Of Guangdong Medical College/CHINA, 3First People Hospital of Zhaoqing/CHINA, 4Fujian Provincial Tumor Hospital/CHINA, 5The Fifth/CHINA, 6Affiliated Hospital of Guangxi Medical College/CHINA 不可切除的III期NSCLC同步放化疗联合重组人血管内抑制素的前瞻性临床研究，中山肿瘤医院陈明教授Background:More than 3000 patients with advanced non-small cell lung cancer (NSCLC) have been treated with recombinant endostatin (endostar) combined with chemotherapy in China. Recently our experimental study showed a synergistic effect between endostar and irradiation in xenografts of Lewis lung in mice. The critical mechanism of which is tumor vasculature normalization occurred in a certain duration. We designed this study to evaluate safety and efficacy of endostar combined with standard current chemoradiation therapy (CCRT) in patients with unresectable stage III NSCLC.Methods:Patients were administered with endostatin 7.5mg/m2 (week0, 2, 4, 6), docetaxel 65mg/m2 (Day 1, 29) and cisplatin 65mg/m2 (Day1, 29). Radiotherapy consists of 2.0 Gy in 30-33 fractions over 6-7 weeks to a total dose of 60-66 Gy. Tumor response was evaluated with thoracic CT scans performed 4 weeks after completion of treatment in accordance with RECIST criteria. Acute toxicities was evaluated with NCI-CTC AE version 3.0Results:From March 2009 to December 2010, 37 patients completed treatment and were available for evaluation. Thirty-three patients remain alive. The median follow-up time was 9.5 months (1-22 months). Six (16.2%) patients achieved complete response (CR), 21 (56.8%) partial response (PR), 6 (16.2%) stable disease (SD), and 4 (10.8%) progressive disease (PD). Endostar did not increase toxicity to CCRT. Hematological and non-hematological toxicities were acceptable. No patient developed cardiovascular toxicity.Table 1. Acute Hematological toxicity Toxicity Grade 1 Grade 2 Grade 3 Grade 4 Leucopenia 15(40.5%) 5(13.5%) 5(13.5%) 11(29.7%) Neutropenia 4(10.8%) 3(8.1%) 4(10.8%) 10(27.0%) Lymphocytopenia 2(5.4%) 3(8.1%) 19(51.4%) 12(32.4%) Anemia 18(48.6%) 5(13.5%) 1(2.7%) 0 Thrombocytopenia 3(8.1%) 4(10.8%) 2(5.4%) 0 Table 2. Acute Non-hematological toxicityConclusion:The preliminary results showed that endostar combined with CCRT for unresectable stage III NSCLC was safe and the short term outcomes were promising. Further investigation is warranted.。
荟萃分析
5、分析
在荟萃分析中，齐性检验是重要的一环，目的是检查各个试验结果是否具有一致性。一般来讲，仅仅由于抽样误差造成的各试验间结果不同，不会影响荟萃分析结果的可靠性。但若发现不一致性的原因是某种特殊因素所致，如某个研究失访病例过多，则不应该将这个试验结果列入荟萃分析。常用的齐性检验方法主要有χ2
荟萃分析 - 荟萃分析的未来
荟萃分析在近20 年来得到了迅速的发展，每年发表的此类文章已经从80 年代的几十篇到2000 年的将近500 篇左右。更有人认为，IPD 荟萃分析应该系统的进行，定期的更新。世界Cochrane 协作网目前正在进行一项庞大的工作，即将全世界所有的随机临床试验进行注册，然后进行相应的荟萃分析。同时，随着信息技术的发展和大型临床试验数据库的不断完善，目前还出现了从回顾型荟萃分析向前瞻型荟萃分转换的趋势，因为后者能更好的避免出版偏倚，更早得到分析结果和医学决策的依据。这一点，相信应能更好的推动 IPD 荟萃分析的步骤
1、计划阶段
首先要确定研究的主题，然后明确本方案的目的，试验的入选标准和排除标准，计划的分析指标，以及准备应用的统计学方法等。一篇荟萃分析最好只研究一个主要问题，但在研究的主要目的明确后，还可以同时研究其他的次要问题。
2、寻找和选择临床试验
理想情况下，所有与研究主题相关的文献都应该包括在荟萃分析之内，不管它是否已经发表。必须考虑到文章出版、语言和引用上的偏倚。一般情况下，显示有统计意义的试验更易被某些杂志刊登，这些论文的发表周期较短，他们有最高的点击指数。通常会用英语发表，他们比未显示出统计学意义的试验被更多的参靠和引用。单单使用计算机进行检索是不够的，尽管这样比较方便。因为即便是象MEDLINE
无疾病进展1 年生存率差（绝对受益）估计值为4.2%，合并危险率比（HR）为0.87，有统计学意义（P<0.001）。所有试验的合并危险率比（HR）为0.90，1 年总生存率的差（绝对受益）估计值为3.9%。对照组的1 年生存率约为35%，健择治疗组约为39%。合并危险率比0.90 的95%可信区间为0.84-0.96，有统计学意义（P<0.001）。亚组分析表明，顺铂单药或第一或二代铂类方案无进展生存率的合并危险率比为0.85，总生存率的合并危险率比为0.89，均有统计学意义。第三代药物/铂类方案无进展生存率的合并危险率比为0.84，总生存率的合并危险率比为0.93，前者有统计学意义，后者95%可信区间为0.86-1.01，接近统计学意义P=0.05 水平。结果为第二个亚组在总生存率方面试验组和对照组无显著性差异，这是唯一不利于健择的数据。
第十届世界肺癌会议英文
Outcome data from IALT
Chemotherapy arm Control
P value
Median survival
50.8 months
➢ 69% of the pts assigned to the chemotherapy arm received all 3 cycles.
➢ Stage Ⅲ disease was present in 28%-29% of pts, while the remainder were stage Ⅰor stage Ⅱ
commentary
➢ NSCLCCG performed a meta-analysis examining the benefit of adjuvant chemotherapy
➢ 17 trials were identified that compared surgery and chemotherapy with surgery alone
Adjuvant lung project ITALY(ALPI)
➢ 1209 pts with completely resected NSCLC were randomly assigned to received either MMC, VDS, and DDP every 3 weeks for 3 cycles or no chemotherapy
Lethal toxicity rate
0.8%
0
The overall survival hazard ratio for chemotherapy was 0.86 95% CI=0.76-0.98 Absolute 5-year survival benefit of 4.1% Absolute 5-year disease-free survival benefit of 5.1%, and hazard ratio was o.83%
肺癌会议发言稿
大家好！今天，我很荣幸能够站在这里，与大家共同探讨肺癌这一严重影响人类健康的重大疾病。
在此，我代表我国肺癌防治领域的同仁们，向各位表示热烈的欢迎和衷心的感谢！一、我国肺癌现状及挑战近年来，我国肺癌发病率和死亡率持续上升，已成为严重威胁我国人民健康的“第一杀手”。
据世界卫生组织（WHO）统计，我国每年新发肺癌患者约70万，占全球新发病例的1/3，每年因肺癌死亡人数约60万。
这一严峻的形势，给我们带来了巨大的挑战。
1. 肺癌发病原因复杂，防治难度大。
吸烟、环境污染、职业暴露、遗传等因素均与肺癌的发生密切相关。
由于肺癌早期症状不明显，不易被察觉，导致早期诊断率低，治疗效果不佳。
2. 肺癌治疗手段有限，治疗效果不佳。
目前，肺癌治疗主要包括手术、化疗、放疗、靶向治疗和免疫治疗等。
然而，这些治疗方法在治疗过程中存在一定的副作用，且治疗效果不尽如人意。
3. 肺癌防治宣传力度不足。
我国肺癌防治知识普及率较低，许多人对于肺癌的早期症状、预防措施和治疗方法了解甚少，导致肺癌患者早期发现率低，错过了最佳治疗时机。
二、我国肺癌防治工作取得的进展面对如此严峻的形势，我国政府高度重视肺癌防治工作，采取了一系列有力措施，取得了显著成效。
1. 加强肺癌防治政策制定。
我国政府制定了一系列肺癌防治政策，如《中国肺癌防治指南》、《肺癌防治规划》等，为肺癌防治工作提供了政策保障。
2. 加大肺癌防治科研投入。
我国加大对肺癌防治科研的投入，支持肺癌基础研究和临床研究，推动肺癌防治技术进步。
3. 提高肺癌诊断水平。
我国积极开展肺癌早期筛查和诊断技术的研究，提高肺癌早期诊断率。
4. 推广肺癌规范化治疗。
我国积极推广肺癌规范化治疗，提高肺癌治疗效果。
5. 加强肺癌防治宣传。
我国加大肺癌防治知识普及力度，提高人民群众对肺癌的认识，增强自我保健意识。
三、我国肺癌防治工作展望面对肺癌防治工作的挑战，我们要坚定信心，共同努力，为实现肺癌防治目标而奋斗。
肺癌英文
2020/4/2
肺癌英文
2
Bronchogenic carcinoma has increased remarkable in incidence and mortality during half of the century and has become the most frequent visceral malignant diseases of men.The mortality of lung cancer hold the first place among all kinds carcinomas.
Passive smoking is also a carcinogen factor.
2020/4/2
肺癌英文
4
2.Atmospheric pollution.It was found that carcinogenic factor is benzpyrene .
3.Occupational factors.
(1).Dysphagia. (2).Hoarseness. (3).Pleural effusion due to invasion of the
pleura.
2020/4/2
肺癌英文
11
(4).Horner’s syndrome.It is caused by invading the cervical sympathetic ganglia on the involved side the pupil is small ptosis of the up eyelids,retraction of the eyeball and no sweat of the face.
2020/4/2
肺癌英文演讲稿
肺癌英文演讲稿Ladies and gentlemen,Today, I stand before you to shed light on a matter of great importance –lung cancer. It is an unfortunate reality that lung cancer continues to be one of the leading causes of death worldwide. Not only does it claim millions of lives each year, but it also inflicts immense pain and suffering on both the patients and their loved ones. We must unite in our efforts to tackle this deadly disease and raise awareness about its prevention and early detection.First and foremost, it is crucial to understand the risk factors associated with lung cancer. Smoking cigarettes is by far the most significant risk factor, accounting for around 85% of all lung cancer cases. The toxic chemicals present in cigarettes, such as tar and nicotine, damage the lung tissues and increase the likelihood of developing cancer. Therefore, the simplest and most effective way to prevent lung cancer is to quit smoking and avoid exposure to secondhand smoke.However, it is essential to note that non-smokers are not excluded from the risk of developing lung cancer. Radon, a naturally occurring radioactive gas, is the second leading cause of lung cancer and can seepinto homes through cracks in the foundation. Consequently, it is crucial to conduct regular radon testing and take measures to reduce its presence if necessary.Furthermore, occupational exposure to carcinogens such as asbestos, arsenic, and certain chemicals can also increase the risk of lung cancer. Therefore, individuals working in industries where such exposure is possible should adhere to safety protocols and use protective gear to minimize the risk.Early detection is undoubtedly a game-changer when it comes to lung cancer. The survival rate for early-stage lung cancer is significantly higher than for advanced cases. Thus, it is essential for individuals at high risk, such as long-term smokers or those with a family history of lung cancer, to undergo regular screenings and diagnostic tests.Education plays a pivotal role in fostering a profound understanding of the importance of prevention and early detection. Schools, communities, and healthcare institutions must collaborate to raise awareness about the risks of smoking and encourage healthy lifestyle choices. Engaging in public campaigns, organizing seminars, and distributing informative pamphlets are just a few ways to disseminate crucial knowledge andpromote positive change.Lastly, we must support research and development efforts to find more effective treatments for lung cancer. Innovative therapies, such as immunotherapy, targeted therapy, and gene therapy, have shown promising results in extending the lives of lung cancer patients. Investing in scientific advancements and clinical trials can lead to breakthroughs that revolutionize the treatment landscape and offer hope to countless individuals battling this disease.In conclusion, lung cancer poses a significant threat to public health, causing immense harm and claiming countless lives each year. By focusing on prevention, early detection, education, and research, we can take significant strides towards reducing the burden of lung cancer. Let us stand together in the fight against this deadly disease and work toward a future where lung cancer is no longer a global health crisis.Thank you.。
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
6
International adjuvant lung cancer trial (IALT)
➢ Thoracic radiotherapy was optional ➢ Chemotherapy was administered with 60 days ➢ 35% pts in each arm underwent
➢ The lethal treatment-associated toxicity rate in the chemotherapy arm was 0.8%
Outcome data from IALT
Chemotherapy arm Control
P value
Median survival
50.8 months
➢ 69% of the pts assigned to the chemotherapy arm received all 3 cycles.
➢ Stage Ⅲ disease was present in 28%-29% of pts, while the remainder were stage Ⅰor stage Ⅱ
5-year survival rate
44.5%
Median disease-free survival 40.2 months
5-year disease-free survival rate 39.4%
44.4 months <0.03 40.4% 30.5 months <0.003 34.3%
Highlights from the Tenth World Conference on lung
cancer
Tracey L, Evans The oncologist 2004;9:232-238 The conference was held in Vancouver, Canada
ppt made by leeyong
Lethal toxicity rate
0.8%
0
The overall survival hazard ratio for chemotherapy was 0.86 95% CI=0.76-0.98 Absolute 5-year survival benefit of 4.1% Absolute 5-year disease-free survival benefit of 5.1%, and hazard ratio was o.83%
pneuonectomy and the remainder had lobectomy ➢ 39% of pts in each arm had stage Ⅲ,and 46% had scc
International adjuvant lung cancer trial (IALT)
➢ 74% pts received at least 240mg/m2 of DDP;8% pts assigned to the chemotherapy arm received no chemotherapy
➢ There was no benefit to chemotherapy in terms of overall survival or progression-free survival
➢ The overall survival hazard ratio for chemotherapy was 1.02 (95%CI=0.77-1.35)
The Big Lung Trial (BLT)
➢ Large, multicenter study in the UK ➢ All pts with NSCLC received primary therapy
as determined by stage (surgery, radiation, or BSC) ➢ Pts randomized to receive either three 3weekly cycles of DDP-based chemotherapy ➢ DDP/VDS, MMC/IFO/DDP, MMC/VLB/DDP NVB/DDP, or no chemotherapy
The Big Lung Trial (BLT)
➢ In the subgroup of pts receiving BSC as their primary modality, there was a statistically significant survival benefit for chemotherapy
Adjuvant lung project ITALY(ALPI)
➢ 1209 pts with completely resected NSCLC were randomly assigned to received either MMC, VDS, and DDP every 3 weeks for 3 cycles or no chemotherapy
Chemotherapy used in IALT
Adjuvant chemotherapy regimen
% of the pts
Cisplatin 300-400mg/m2 over 3-4 cycles with
e7
vinblastin
11
vindesine
Adjuvant Chemotherapy in nonsmall-cell lung cancer
➢ International adjuvant lung cancer trial (IALT) from 1995-2000 1867 pts from 148 centers in 33 countries pts undergone complete resection of NSCLC chemotherapy arm vs observation arm
Adjuvant lung project ITALY(ALPI)